Large-scale testing (Phase 3)Study completedNCT01752634
What this trial is testing
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
Who this might be right for
Psoriatic Arthritis
Novartis Pharmaceuticals 397